The Translational Breast Cancer Research Consortium was well represented at the 2026 ASCO Meeting.  Presentations included:

TBCRC 050: A phase 1b/2 trial of niraparib and trastuzumab in HER2-positive metastatic breast cancer (MBC): Efficacy and correlative analyses; Abstract #1056

Primary results from the triple-negative cohort of TBCRC-053 (P-RAD): A randomized trial of no, low, or high dose preoperative radiation with pembrolizumab and chemotherapy in node-positive breast cancer; Abstract #1011

TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769); Abstract #TPS1162

ETHAN: A phase II study comparing different endocrine therapies for male breast cancer [TBCRC 059]; Abstract #TPS656

A single-arm, phase II study of sequential therapy with curative intent in de novo HER2+ metastatic breast cancer: The SAPPHO study [TBCRC 065]; Abstract #TPS1147

CAPELA: A phase II multicenter open-label randomized study of capecitabine in combination with elacestrant versus capecitabine alone in advanced estrogen receptor (ER)–positive breast cancer (TBCRC 070); Abstract #TPS1156

PREDICT-RD: Postoperative molecular residual disease by ctDNA surveillance in TNBC with residual disease (TBCRC-071); Abstract #TPS647

Phase IIa, open-label, multi-center study of the DNA polymerase theta inhibitor ART6043 administered orally in combination with olaparib to patients with HER2-negative breast cancer with a germline BRCA1/2 mutation (randomized expansion of study NCT05898399) [TBCRC 076]; Abstract #TPS1165